URMC / Labs / Looney Lab / Publications Publications Gao LSlack MBarnas JLMcDavid AAnolik JLooney RJ Correction to: Cell Senescence in Lupus.; Current rheumatology reports; Vol 21(7). 2019 May 23. Gao LSlack MMcDavid AAnolik JLooney RJ Cell Senescence in Lupus.; Current rheumatology reports; Vol 21(2). 2019 Jan 14. Gao LBird AKMeednu NDauenhauer KLiesveld JAnolik JLooney RJ Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon-β Feedback Loop.; Arthritis & rheumatology (Hoboken, N.J.); Vol 69(8). 2017 Aug. Martina CLooney RJMarcus CAllen MStahlhut R Prevalence of allergic disease in Old Order Mennonites in New York.; Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology; Vol 117(5). 2016 Jan. Adlowitz DGBarnard JBiear JNCistrone COwen TWang WPalanichamy AEzealah ECampbell DWei CLooney RJSanz IAnolik JH Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.; PloS one; Vol 10(6). 2015. Stohl WMerrill JTLooney RJBuyon JWallace DJWeisman MHGinzler EMCooke BHolloway DKaliyaperumal AKuchimanchi KRCheah TCRasmussen EFerbas JBelouski SSTsuji WZack DJ Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.; Arthritis research & therapy; Vol 17. 2015. Rovin BHFurie RLatinis KLooney RJFervenza FCSanchez-Guerrero JMaciuca RZhang DGarg JPBrunetta PAppel G Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.; Arthritis and rheumatism; Vol 64(4). 2012 Apr. Ichikawa HTConley TMuchamuel TJiang JLee SOwen TBarnard JNevarez SGoldman BIKirk CJLooney RJAnolik JH Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.; Arthritis and rheumatism; Vol 64(2). 2012 Feb. Kobie JJZheng BBryk PBarnes MRitchlin CTTabechian DAAnandarajah APLooney RJThiele RGAnolik JHCoca AWei CRosenberg AFFeng CTreanor JJLee FESanz I Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.; Arthritis research & therapy; Vol 13(6). 2011. Qi YOperario DJOberholzer CMKobie JJLooney RJGeoras SNMosmann TR Human basophils express amphiregulin in response to T cell-derived IL-3.; The Journal of allergy and clinical immunology; Vol 126(6). 2010 Dec. Marston BLooney RJ Connective tissue diseases: Translating the effects of BAFF in SLE.; Nature reviews. Rheumatology; Vol 6(9). 2010 Sep. Looney RJ B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.; Drugs; Vol 70(5). 2010 Mar 26. Looney RJAnolik JSanz I A perspective on B-cell-targeting therapy for SLE.; Modern rheumatology / the Japan Rheumatism Association; Vol 20(1). 2010 Feb. Kwon JBKleiner AIshida KGodown JCiafaloni ELooney RJ Hydroxychloroquine-induced myopathy.; Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases; Vol 16(1). 2010 Jan. Bingham COLooney RJDeodhar AHalsey NGreenwald MCodding CTrzaskoma BMartin FAgarwal SKelman A Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.; Arthritis and rheumatism; Vol 62(1). 2010 Jan. Anolik JHLooney RJLund FERandall TDSanz I Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets.; Immunologic research; Vol 45(2-3). 2009 Dec. Coca ABundy KWMarston BHuggins JLooney RJ Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin.; Clinical immunology (Orlando, Fla.); Vol 132(1). 2009 Jul. Palanichamy ABarnard JZheng BOwen TQuach TWei CLooney RJSanz IAnolik JH Novel human transitional B cell populations revealed by B cell depletion therapy.; Journal of immunology (Baltimore, Md. : 1950); Vol 182(10). 2009 May 15. Brown RJRother KIArtman HMercurio MGWang RLooney RJCowen EW Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae.; Archives of dermatology; Vol 145(1). 2009 Jan. Looney RJ Update on the use of rituximab for intractable rheumatoid arthritis.; Open access rheumatology : research and reviews; Vol 1. 2009. Albert DDunham JKhan SStansberry JKolasinski STsai DPullman-Mooar SBarnack FStriebich CLooney RJPrak ETKimberly RZhang YEisenberg R Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.; Annals of the rheumatic diseases; Vol 67(12). 2008 Dec. Kleiner ALooney RJ Is rituximab suitable for use as a first-line biologic therapy for RA?; Nature clinical practice. Rheumatology; Vol 4(11). 2008 Nov. Mehta LRSamuelsson MKKleiner AKGoodman ADAnolik JHLooney RJSchwid SR Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome.; Multiple sclerosis (Houndmills, Basingstoke, England); Vol 14(3). 2008 Apr. Nicholas MWDooley MAHogan SLAnolik JLooney JSanz IClarke SH A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE.; Clinical immunology (Orlando, Fla.); Vol 126(2). 2008 Feb. Looney RJSrinivasan RCalabrese LH The effects of rituximab on immunocompetency in patients with autoimmune disease.; Arthritis and rheumatism; Vol 58(1). 2008 Jan. Brown RJRother KIMercurio MGWang RLooney RJCowen EW Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae; Archives of Dermatology. 2008 Jan 01. Kleiner ALooney RJ Commentary: rituximab as first line therapy for rheumatoid arthritis; Nature Clinical Practice in Rheumatology. 2008 Jan 01. Reddy MBLooney RJUtell MJPlotzke KPAndersen ME Modeling of human dermal absorption of octamethylcyclotetrasiloxane (D(4)) and decamethylcyclopentasiloxane (D(5)).; Toxicological sciences : an official journal of the Society of Toxicology; Vol 99(2). 2007 Oct. Ravikumar RAnolik JLooney RJ Vaccine responses in patients with rheumatoid arthritis.; Current rheumatology reports; Vol 9(5). 2007 Oct. Anolik JHBarnard JOwen TZheng BKemshetti SLooney RJSanz I Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.; Arthritis and rheumatism; Vol 56(9). 2007 Sep. Looney RJStohl W New and promising treatments for rheumatoid arthritis.; American journal of orthopedics (Belle Mead, N.J.); Vol 36(7 Suppl). 2007 Jul. Looney RJDiamond BHolers VMLevesque MCMoreland LNahm MHSt Clair EW Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases.; Clinical immunology (Orlando, Fla.); Vol 123(3). 2007 Jun. Looney RJ Will targeting B cells be the answer for Sjögren's syndrome?; Arthritis and rheumatism; Vol 56(5). 2007 May. Sanz IAnolik JHLooney RJ B cell depletion therapy in autoimmune diseases.; Frontiers in bioscience : a journal and virtual library; Vol 12. 2007. Anolik JHBarnard JOwen TZheng BKemshetti SLooney RJSanz I Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy; Arthritis & Rheumatism; Vol 56(9), pp. 3004-3056. 2007 Jan 01. Ravikumar RAnolik JLooney R Vaccine responses in patients with rheumatoid arthritis; Current Rheumatology Reports; Vol 9(5), pp. 407-415. 2007 Jan 01. Stohl WLooney RJ B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?; Clinical immunology (Orlando, Fla.); Vol 121(1). 2006 Oct. Schwarz EMLooney RJDrissi MHO'Keefe RJBoyce BFXing LRitchlin CT Autoimmunity and bone.; Annals of the New York Academy of Sciences; Vol 1068. 2006 Apr. Looney RJAnolik JSanz I New therapies for systemic lupus erythematosus: cellular targets.; Rheumatic diseases clinics of North America; Vol 32(1). 2006 Feb. Looney RJSchwarz EMBoyd AO'Keefe RJ Periprosthetic osteolysis: an immunologist's update.; Current opinion in rheumatology; Vol 18(1). 2006 Jan. Looney RJHuggins J Use of intravenous immunoglobulin G (IVIG).; Best practice & research. Clinical haematology; Vol 19(1). 2006. Looney RJ B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.; Drugs; Vol 66(5). 2006. Schwarz EMLooney RJDrissi HO'Keefe RJBoyce BFZing LRitchlin CT Autoimmunity and bone; Annals of the New York Academy of Science; Vol 1068, pp. 275-283. 2006 Jan 01. Looney RJ B cell-targeted therapy for rheumatoid arthritis: an update on the evidence; Drugs; Vol 66, pp. 325-339. 2006 Jan 01. Eisenberg RLooney RJ The therapeutic potential of anti-CD20 "what do B-cells do?".; Clinical immunology (Orlando, Fla.); Vol 117(3). 2005 Dec. Looney RJ Discovering that B cells are important in rheumatoid arthritis.; The Journal of rheumatology; Vol 32(11). 2005 Nov. Looney RJAnolik JSanz I Treatment of SLE with anti-CD20 monoclonal antibody.; Current directions in autoimmunity; Vol 8. 2005. Schwarz EMO'Keefe RJZing LLooney RJRitchlin CT Receptor activator of nuclear kappa ligand and osteoprotegerin: where are we now and what about future treatment uses?; Current Opinion in Orthopedics; Vol 16, pp. 370-375. 2005 Jan 01. Anolik JHBarnard JCappione APugh-Bernard AEFelgar RELooney RJSanz I Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.; Arthritis and rheumatism; Vol 50(11). 2004 Nov. Huggins JLLooney RJ Allergen immunotherapy.; American family physician; Vol 70(4). 2004 Aug 15. View all publications